You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Innovation Passport awarded Alnylam and its hypertension therapy

Alnylam Pharmaceuticals has announced that zilebesiran – an investigational RNAi therapy targeting liver-expressed angiotensinogen – has been awarded an Innovation Passport for the treatment of hypertension by the Medicines and Healthcare products Regulatory Agency (MHRA).